Literature DB >> 12520698

Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia.

Majed A Refaai1, Michael Laposata, Elizabeth M Van Cott.   

Abstract

We studied the usefulness of repeated enzyme-linked immunosorbent assay testing for heparin-induced thrombocytopenia (HIT) when the initial test result was negative and sought to determine whether the titer of the initial negative result correlated with the likelihood of obtaining a positive test result in repeated testing. We divided 150 patients who underwent HIT testing into 3 groups (50 patients each): (1) very low titer negative (0.0%-33.3% of the threshold for a positive test); (2) low titer negative (33.4%-66.6% of the threshold); and (3) high titer negative (66.7%-99.9% of the threshold). Among the patients who underwent a repeat test, 5% (1/20) of group 1 patients, 13% (4/32) of group 2 patients, and 43% (13/30) of group 3 patients tested positive in the repeat test (P = .0026). Thus, nearly half of patients with initially negative HIT test results had positive results in the repeat test if the negative titer was 66.7% or more of the threshold. If laboratories report the HIT titer, rather than just negative or positive, the titer might help clinicians predict which patients have HIT despite a negative initial test, and the overall sensitivity for diagnosing HIT might be improved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12520698     DOI: 10.1309/6922-EWGP-HVDX-9EQJ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.

Authors:  Lubica Rauova; Li Zhai; M Anna Kowalska; Gowthami M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

Review 2.  Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results.

Authors:  Gowthami M Arepally; Marcie J Hursting
Journal:  J Thromb Thrombolysis       Date:  2008-03-28       Impact factor: 2.300

3.  Evaluation of a rapid and automated heparin-induced thrombocytopenia immunoassay.

Authors:  Majed A Refaai; Grace Conley; Thomas L Ortel; John L Francis
Journal:  Int J Lab Hematol       Date:  2019-04-15       Impact factor: 2.877

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.